A Randomized, Double Blind Study to Evaluate the Efficacy and Safety of Two Atypical Antipsychotics vs. Placebo in Patients With an Acute Exacerbation of Either Schizophrenia or Schizoaffective Disorder

NCT00061802 Phase 4 COMPLETED

A study to evaluate the efficacy and safety of two atypical antipsychotics vs. placebo in patients with an acute exacerbation of either schizophrenia or schizoaffective disorder

Details

Lead sponsor	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase	Phase 4
Status	COMPLETED
Enrolment	225
Start date	2003-06
Completion	2004-02

Conditions

• Schizophrenia
• Schizoaffective Disorder

Interventions

• risperidone, quetiapine

Primary outcomes

• Efficacy of combined risperidone and quetiapine groups versus placebo based on change in psychotic symptoms scale from baseline to two weeks.

Countries

United States, India, Romania